|
|
|
|
|
Trospium
drug data and news
Trospium drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Trospium | ||
| Brand Names/Synonyms | Sanctura; Trospium Chloride; Trospium Spiroalcohol | ||
| Indication | For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, Detrusor instability and frequency of micturition | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Receptor assays showed that trospium chloride has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses. | ||
| Mechanism Of Action | Trospium chloride antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder. | ||
| Trospium News (When available) |
| ||
| Dosage Forms | Tablet | ||
| Drug_Category | Analgesics; ATC:G04BD09 | ||
| Absorption | 9.60% | ||
| Interactions |
-->Interactions for Trospium: The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway. Careful patient monitoring is recommended in patients receiving such drugs. Drug-Laboratory-Test Interactions Interactions between Sanctura and laboratory tests have not been studied. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C25H30NO3 | ||
| Molecular Weight | 392.511 g/mol | ||
| Smiles String | C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not fully defined | ||
| Half Life | 20 hours | ||
| Protein Binding [%] | 50-85% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Trospium.html http://www.rxlist.com/cgi/generic3/sanctura.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00393 | ||
| CAS Registry Number | 10405-02-4 | ||
| KEGG Compound ID | D01103 | ||
| PubChem ID | SID:7848166 | ||
| PharmGKB ID | PA10221 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |